148 related articles for article (PubMed ID: 12063551)
1. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Agrawal S; Kandimalla ER; Yu D; Ball R; Lombardi G; Lucas T; Dexter DL; Hollister BA; Chen SF
Int J Oncol; 2002 Jul; 21(1):65-72. PubMed ID: 12063551
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
[TBL] [Abstract][Full Text] [Related]
3. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
4. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
Agrawal S; Kandimalla ER; Yu D; Hollister BA; Chen SF; Dexter DL; Alford TL; Hill B; Bailey KS; Bono CP; Knoerzer DL; Morton PA
Int J Oncol; 2001 May; 18(5):1061-9. PubMed ID: 11295057
[TBL] [Abstract][Full Text] [Related]
6. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
Wang H; Cai Q; Zeng X; Yu D; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13989-94. PubMed ID: 10570186
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
10. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
Tortora G; Bianco R; Damiano V; Fontanini G; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Jun; 6(6):2506-12. PubMed ID: 10873106
[TBL] [Abstract][Full Text] [Related]
11. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
12. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
[TBL] [Abstract][Full Text] [Related]
13. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
15. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
[TBL] [Abstract][Full Text] [Related]
16. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
[TBL] [Abstract][Full Text] [Related]
17. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
18. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
Mani S; Goel S; Nesterova M; Martin RM; Grindel JM; Rothenberg ML; Zhang R; Tortora G; Cho-Chung YS
Ann N Y Acad Sci; 2003 Dec; 1002():252-62. PubMed ID: 14751840
[TBL] [Abstract][Full Text] [Related]
19. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
Hensley HH; Hannoun-Levi JM; Hachem P; Mu Z; Stoyanova R; Khor LY; Agrawal S; Pollack A
Int J Cancer; 2011 Feb; 128(4):962-73. PubMed ID: 20960462
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
